BACKGROUND: The purpose of the Spanish Lung Cancer Anaemia Survey (SLCAS) was to thoroughly investigate lung cancer-associated anaemia management, and describe the profile of lung cancer patients in relation to anaemia incidence and tumour type in Spain. PATIENTS AND METHODS: This survey collected data from 1089 randomly recruited patients gathered by 50 Spanish physicians at 38 sites. In addition, a qualitative assay was performed through 16 one-to-one and 2 one-to-two interviews, and a discussion group of 4 cancer specialists participating in the survey. RESULTS: Lung cancer patients undergoing chemotherapy treatment had haemoglobin (Hb) levels <12.0 g/dl in 58.0% of the cases, in contrast to 39.0% of patients receiving no chemotherapy. Anaemia was treated in 53.0% of patients with Hb<12 g/dl (45.0% epoetin, 3.9% transfusion, 4.1% iron). Mean Hb level trigger was 9.7 g/dl for administration of epoetin and 8.2 g/dl for blood transfusion. CONCLUSIONS: SLCAS reveals a significant change in the management of anaemia and clinical practice pattern in the use of erythropoiesis-stimulating agents (45.0% vs. 18.0%) and much less use of blood transfusions (3.9% vs. 15.0%) since the European Cancer Anaemia Survey performed five years ago.
BACKGROUND: The purpose of the Spanish Lung Cancer Anaemia Survey (SLCAS) was to thoroughly investigate lung cancer-associated anaemia management, and describe the profile of lung cancerpatients in relation to anaemia incidence and tumour type in Spain. PATIENTS AND METHODS: This survey collected data from 1089 randomly recruited patients gathered by 50 Spanish physicians at 38 sites. In addition, a qualitative assay was performed through 16 one-to-one and 2 one-to-two interviews, and a discussion group of 4 cancer specialists participating in the survey. RESULTS:Lung cancerpatients undergoing chemotherapy treatment had haemoglobin (Hb) levels <12.0 g/dl in 58.0% of the cases, in contrast to 39.0% of patients receiving no chemotherapy. Anaemia was treated in 53.0% of patients with Hb<12 g/dl (45.0% epoetin, 3.9% transfusion, 4.1% iron). Mean Hb level trigger was 9.7 g/dl for administration of epoetin and 8.2 g/dl for blood transfusion. CONCLUSIONS: SLCAS reveals a significant change in the management of anaemia and clinical practice pattern in the use of erythropoiesis-stimulating agents (45.0% vs. 18.0%) and much less use of blood transfusions (3.9% vs. 15.0%) since the European Cancer Anaemia Survey performed five years ago.
Authors: J Douglas Rizzo; Melissa Brouwers; Patricia Hurley; Jerome Seidenfeld; Murat O Arcasoy; Jerry L Spivak; Charles L Bennett; Julia Bohlius; Darren Evanchuk; Matthew J Goode; Ann A Jakubowski; David H Regan; Mark R Somerfield Journal: Blood Date: 2010-10-25 Impact factor: 22.113
Authors: C Bokemeyer; M S Aapro; A Courdi; J Foubert; H Link; A Osterborg; L Repetto; P Soubeyran Journal: Eur J Cancer Date: 2006-12-19 Impact factor: 9.162
Authors: Gunnar Birgegård; Matti S Aapro; Carsten Bokemeyer; Mario Dicato; Peter Drings; Javier Hornedo; Maciej Krzakowski; Heinz Ludwig; Sergio Pecorelli; Hans Schmoll; Maurice Schneider; Dirk Schrijvers; Daniel Shasha; Simon Van Belle Journal: Oncology Date: 2005 Impact factor: 2.935
Authors: Mark Vincent; George Dranitsaris; Sunil Verma; Cathy Lau; Pere Gascon; Simon Van Belle; Heinz Ludwig Journal: Support Care Cancer Date: 2006-11-21 Impact factor: 3.603
Authors: Javier de Castro; Cristóbal Belda-Iniesta; Dolores Isla; Manuel Dómine; Alfredo Sánchez; Eduard Batiste; Manuel González Barón Journal: Lung Cancer Date: 2007-09-17 Impact factor: 5.705
Authors: Peter J Barrett-Lee; Heinz Ludwig; Gunnar Birgegård; Carsten Bokemeyer; Pere Gascón; Paris A Kosmidis; Maciej Krzakowski; Johan W R Nortier; Gail Kongable; Maurice Schneider; Dirk Schrijvers; Simon J Van Belle Journal: Oncology Date: 2006-02-21 Impact factor: 2.935